- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Clears Investigational New Drug Application for Lipella’s Oral Lichen Planus Treatment
LP-310 designated as an oral formulation of company’s LP-10 asset.
Lipella Pharmaceuticals announced that the FDA has approved an investigational new drug (IND) application for a multi-center, Phase IIa, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP). In March of this year, the organization created a scientific advisory board to focus on the development of LP-310.
"OLP is a painful oral mucosal disease that currently has no approved therapy. We look forward to the opportunity to develop an effective treatment,” said Michael Chancellor, MD, chief medical officer, Lipella, in a company press release.
Reference: Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus. PR Newswire. October 20, 2023. Accessed October 20, 2023. https://www.prnewswire.com/news-releases/lipella-pharmaceuticals-announces-fda-clearance-of-ind-for-lp-310-for-oral-lichen-planus-301962718.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
